WO2000047236A8 - Matrices for drug delivery and methods for making and using the same - Google Patents
Matrices for drug delivery and methods for making and using the sameInfo
- Publication number
- WO2000047236A8 WO2000047236A8 PCT/US2000/003754 US0003754W WO0047236A8 WO 2000047236 A8 WO2000047236 A8 WO 2000047236A8 US 0003754 W US0003754 W US 0003754W WO 0047236 A8 WO0047236 A8 WO 0047236A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- matrices
- making
- methods
- same
- drug delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/552—Glass or silica
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2328614A CA2328614C (en) | 1999-02-12 | 2000-02-14 | Matrices for drug delivery and methods for making and using the same |
AU27599/00A AU772153B2 (en) | 1999-02-12 | 2000-02-14 | Matrices for drug delivery and methods for making and using the same |
JP2000598187A JP4812167B2 (en) | 1999-02-12 | 2000-02-14 | Drug transport matrix and methods for making and using the same |
IL13899000A IL138990A0 (en) | 1999-02-12 | 2000-02-14 | Matrices for drug delivery and methods for making and using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11982899P | 1999-02-12 | 1999-02-12 | |
US60/119,828 | 1999-02-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000047236A1 WO2000047236A1 (en) | 2000-08-17 |
WO2000047236A8 true WO2000047236A8 (en) | 2001-04-19 |
Family
ID=22386633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/003754 WO2000047236A1 (en) | 1999-02-12 | 2000-02-14 | Matrices for drug delivery and methods for making and using the same |
Country Status (6)
Country | Link |
---|---|
US (4) | US6395299B1 (en) |
JP (1) | JP4812167B2 (en) |
AU (1) | AU772153B2 (en) |
CA (1) | CA2328614C (en) |
IL (1) | IL138990A0 (en) |
WO (1) | WO2000047236A1 (en) |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6764690B2 (en) * | 1996-05-29 | 2004-07-20 | Delsitech Oy | Dissolvable oxides for biological applications |
JP4533531B2 (en) * | 1998-04-03 | 2010-09-01 | ビーエム リサーチ エイ/エス | Controlled release composition |
US6896874B2 (en) * | 1998-05-26 | 2005-05-24 | Wisconsin Alumni Research Foundation | MR-signal emitting coatings |
US6361759B1 (en) * | 1998-05-26 | 2002-03-26 | Wisconsin Alumni Research Foundation | MR signal-emitting coatings |
US7118921B1 (en) * | 1999-06-24 | 2006-10-10 | Mcmaster University | Incorporation and applications of biomolecular interactions within a carrier |
US20030162241A1 (en) * | 2000-04-17 | 2003-08-28 | Fritz Pittner | Method for determining the concentration of carnitine in fluids |
JP4979109B2 (en) | 2000-04-21 | 2012-07-18 | ゾル−ゲル テクノロジーズ リミテッド | Compositions showing enhanced formulation stability and delivery of topical active ingredients |
US7758888B2 (en) | 2000-04-21 | 2010-07-20 | Sol-Gel Technologies Ltd. | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
US6592860B1 (en) * | 2000-05-30 | 2003-07-15 | Soluble Systems, Llc | Composition and applicator for topical substance delivery |
JP2004525621A (en) * | 2001-01-18 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Bifunctional fusion protein having glucocerebrosidase activity |
US6977171B1 (en) | 2001-04-03 | 2005-12-20 | University Of Florida | Detoxification and decontamination using nanotechnology therapy |
WO2002080885A1 (en) | 2001-04-03 | 2002-10-17 | University Of Florida | Detoxification and decontamination using nanotechnology therapy |
GB0116853D0 (en) * | 2001-07-10 | 2001-09-05 | Torsana Diabetes Diagnostics A | Optical sensor containing particles for in SITU measurement of analytes |
US20040253310A1 (en) * | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
EP1429739A1 (en) * | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
DE60335608D1 (en) * | 2002-02-27 | 2011-02-17 | Pharmain Corp | COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
GB0205772D0 (en) * | 2002-03-12 | 2002-04-24 | Gill Steven S | Catheter |
EP1534295A4 (en) * | 2002-07-17 | 2009-08-05 | Chemgenex Pharmaceuticals Inc | Formulations and methods of administration of cephalotaxines, including homoharringtonine |
US20040241242A1 (en) * | 2002-12-06 | 2004-12-02 | Kosmos Pharma | Thin film delivery systems for volatile decongestants |
ITMI20022777A1 (en) * | 2002-12-27 | 2004-06-28 | Altergon Sa | PHARMACEUTICAL FORMULATIONS FOR THYROID HORMONES AND PROCEDURES FOR THEIR OBTAINING. |
WO2004081222A2 (en) | 2003-03-14 | 2004-09-23 | Sol-Gel Technologies Ltd. | Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same |
EP2301526B1 (en) * | 2003-03-26 | 2016-03-23 | Egalet Ltd. | Morphine controlled release system |
JP4989217B2 (en) * | 2003-03-26 | 2012-08-01 | エガレット エイ/エス | Matrix composition for controlled delivery of drug substance |
US20040234962A1 (en) * | 2003-05-02 | 2004-11-25 | Javier Alarcon | Multicoated or multilayer entrapment matrix for protein biosensor |
DE10321082A1 (en) * | 2003-05-09 | 2004-11-25 | Basf Ag | Process for the preparation of a hydroxylation catalyst and its use |
US7067169B2 (en) * | 2003-06-04 | 2006-06-27 | Chemat Technology Inc. | Coated implants and methods of coating |
EP2263788B1 (en) | 2003-07-31 | 2018-07-25 | Sol-Gel Technologies Ltd. | A process for the preparation of microcapsules filled with active ingredients |
EP1663159A4 (en) * | 2003-09-10 | 2010-06-09 | Map Pharmaceuticals Inc | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
US20050095690A1 (en) * | 2003-10-31 | 2005-05-05 | Naik Rajesh R. | Entrapment of biomolecules and inorganic nanoparticles by biosilicification |
US20050095174A1 (en) * | 2003-10-31 | 2005-05-05 | Wolf David E. | Semipermeable sensors for detecting analyte |
US7642077B2 (en) * | 2003-12-08 | 2010-01-05 | Genencor International, Inc. | Biocomposite comprising co-precipitate of enzyme, silicate and polyamine |
US8097269B2 (en) * | 2004-02-18 | 2012-01-17 | Celonova Biosciences, Inc. | Bioactive material delivery systems comprising sol-gel compositions |
US7981441B2 (en) * | 2004-02-18 | 2011-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Drug delivery systems using mesoporous oxide films |
GB0420016D0 (en) * | 2004-09-09 | 2004-10-13 | Leuven K U Res & Dev | Controlled release oral delivery system |
EP1814984A2 (en) * | 2004-09-17 | 2007-08-08 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
CA2581896C (en) | 2004-09-29 | 2015-11-10 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
US20060079514A1 (en) * | 2004-10-13 | 2006-04-13 | Victory Pharma Incorporated | Methods and compositions including methscopolamine bromide |
US20060079513A1 (en) * | 2004-10-13 | 2006-04-13 | Preston David M | Methods and compositions including methscopolamine nitrate |
MX2007007373A (en) | 2004-12-20 | 2007-08-14 | Australian Nuclear Science Tec | Controlled release of biological entities. |
US8128952B2 (en) * | 2005-01-12 | 2012-03-06 | Clemson University Research Foundation | Ligand-mediated controlled drug delivery |
WO2006099207A2 (en) | 2005-03-10 | 2006-09-21 | Diversa Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
EP1895989A2 (en) * | 2005-06-03 | 2008-03-12 | Egalet A/S | A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
JP5164840B2 (en) | 2005-08-02 | 2013-03-21 | ソル − ゲル テクノロジーズ リミテッド | Metal oxide coating for water-insoluble components |
US7838526B2 (en) * | 2005-08-05 | 2010-11-23 | Esther Baldinger | Method of treating neurological disorders |
US20080254082A1 (en) | 2005-09-27 | 2008-10-16 | Sol-Gel Technologies Ltd. | Methods for Crop Protection |
KR101369388B1 (en) * | 2005-11-14 | 2014-03-06 | 바이오메트 쓰리아이 엘엘씨 | Deposition of discrete nanoparticles on an implant surface |
AU2013273733B2 (en) * | 2005-11-16 | 2015-12-24 | Pro Natura Gesellschaft Fur Gesunde Ernahrung Mbh | Agent for use in the case of fructose intolerance |
DE102006012244A1 (en) * | 2005-11-16 | 2007-05-31 | Pro Natura Gesellschaft für gesunde Ernährung mbH | New 5-D-fructose dehydrogenase, optionally in combination with invertase, maltase and/or glucose isomerase, useful in therapy or diagnosis of disorders of fructose metabolism, including fructose intolerance |
EP3318271A1 (en) * | 2005-11-16 | 2018-05-09 | Pro Natura Gesellschaft für Gesunde Ernährung mbH | Agent for use in the case of fructose intolerance |
DE102006013624B4 (en) * | 2005-11-23 | 2012-03-15 | Pro Natura Gesellschaft für gesunde Ernährung mbH | Means for use in fructose intolerance |
EP1951293B1 (en) * | 2005-11-23 | 2015-09-09 | Pro Natura Gesellschaft für Gesunde Ernährung mbH | Agent for use in the case of disorders of blood sugar metabolism, including diabetes |
DE102005056103A1 (en) * | 2005-11-23 | 2007-05-24 | Pro Natura Gesellschaft für gesunde Ernährung mbH | Agent, useful to treat diabetes, comprises 5-D-fructose-dehydrogenase and glucose isomerase |
DE102006013623A1 (en) * | 2005-11-23 | 2007-05-24 | Pro Natura Gesellschaft für gesunde Ernährung mbH | New 5-D-fructose-dehydrogenase useful e.g. as a medicament, food, dietetic food, food additives or a balanced diet and for the therapy of adiposity |
AU2006316815A1 (en) * | 2005-11-23 | 2007-05-31 | Pro Natura Gesellschaft Fur Gesunde Ernahrung Mbh | Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity) |
AU2013211517B2 (en) * | 2005-11-23 | 2016-06-30 | Pro Natura Gesellschaft Fur Gesunde Ernahrung Mbh | Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity) |
KR101872061B1 (en) | 2005-12-19 | 2018-06-27 | 파마인 코포레이션 | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
US20070156042A1 (en) * | 2005-12-30 | 2007-07-05 | Orhan Unal | Medical device system and method for tracking and visualizing a medical device system under MR guidance |
US8457712B2 (en) * | 2005-12-30 | 2013-06-04 | Wisconsin Alumni Research Foundation | Multi-mode medical device system and methods of manufacturing and using same |
EP1986701B1 (en) * | 2006-02-24 | 2012-06-13 | Mallinckrodt LLC | Optical agents for use in surgery |
US10278917B2 (en) | 2006-04-14 | 2019-05-07 | Perrigo Israel Pharmaceuticals Ltd. | Pharmaceutical compositions comprising silica microspheres |
US8920821B2 (en) | 2006-04-14 | 2014-12-30 | Perrigo Israel Pharmaceuticals Ltd. | Pharmaceutical compositions comprising silica microspheres |
EP2020987B1 (en) * | 2006-06-06 | 2013-10-30 | Universidad Autónoma Metropolitana | Sol-gel nanostructured titania reservoirs for use in the controlled release of drugs in the central nervous system and method of synthesis |
US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
WO2008036449A2 (en) * | 2006-06-29 | 2008-03-27 | The Regents Of The University Of California | Chemical antibodies for immunotherapy and imaging |
DE102006038629A1 (en) * | 2006-08-17 | 2008-02-21 | Dr. Suwelack Skin & Health Care Ag | Stabilized active ingredient composition |
ATE475686T1 (en) | 2006-10-31 | 2010-08-15 | Surmodics Pharmaceuticals Inc | SPHERICAL POLYMER PARTICLES |
US8532742B2 (en) * | 2006-11-15 | 2013-09-10 | Wisconsin Alumni Research Foundation | System and method for simultaneous 3DPR device tracking and imaging under MR-guidance for therapeutic endovascular interventions |
WO2008086804A2 (en) * | 2007-01-16 | 2008-07-24 | Egalet A/S | Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
US20080183070A1 (en) * | 2007-01-29 | 2008-07-31 | Wisconsin Alumni Research Foundation | Multi-mode medical device system with thermal ablation capability and methods of using same |
ES2912051T3 (en) | 2007-02-01 | 2022-05-24 | Sol Gel Tech Ltd | Compositions for topical application comprising a peroxide and retinoid |
MX352876B (en) * | 2007-02-01 | 2017-12-13 | Sol Gel Tech Ltd | Method for preparing particles comprising metal oxide coating and particles with metal oxide coating. |
KR20090129998A (en) | 2007-02-11 | 2009-12-17 | 맵 파마슈티컬스, 인코포레이티드 | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
DE102007008664B4 (en) * | 2007-02-20 | 2021-07-29 | Vitacare Gmbh & Co. Kg | Means for use in fructose intolerance |
US8412306B2 (en) * | 2007-02-28 | 2013-04-02 | Wisconsin Alumni Research Foundation | Voltage standing wave suppression for MR-guided therapeutic interventions |
WO2008150845A1 (en) * | 2007-05-31 | 2008-12-11 | Vanderbilt University | Screening for wnt pathway modulators and pyrvinium for the treatment of cance |
US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
KR100860958B1 (en) * | 2007-08-08 | 2008-09-30 | 전남대학교산학협력단 | A multi-channel bioreactor with the immobillization of optical sensing membrane |
US7560263B2 (en) * | 2007-08-17 | 2009-07-14 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
JP2009044997A (en) * | 2007-08-20 | 2009-03-05 | Sony Corp | Method for coating bod (bilirubin oxidase) |
WO2009088385A1 (en) * | 2008-01-04 | 2009-07-16 | Capricorn Pharma Inc. | Resin-complex granulation for water-soluble drugs and associated methods |
US20090176892A1 (en) | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
ES2545781T3 (en) * | 2008-01-28 | 2015-09-15 | Biomet 3I, Llc | Superficial implant with greater hydrophilicity |
WO2009114520A2 (en) * | 2008-03-10 | 2009-09-17 | Pharmain Corporation | Compositions for treatment with metallopeptidases, methods of making and using the same |
GB0805279D0 (en) * | 2008-03-20 | 2008-04-30 | Univ Nottingham Trent | Food supplement |
US9114125B2 (en) | 2008-04-11 | 2015-08-25 | Celonova Biosciences, Inc. | Drug eluting expandable devices |
DE102008033327A1 (en) * | 2008-07-16 | 2010-01-21 | Bayer Innovation Gmbh | Silica sol material having at least one therapeutically active agent for the production of biodegradable and / or resorbable silica gel materials for human medicine and / or medical technology |
WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
EP2151466A1 (en) * | 2008-08-01 | 2010-02-10 | SiNatur GmbH | Biologically active silicic acid |
EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
EP2246065A1 (en) * | 2009-04-29 | 2010-11-03 | Merz Pharma GmbH & Co. KGaA | Intrastriatal botulinum toxin therapy |
NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
WO2011097335A2 (en) | 2010-02-04 | 2011-08-11 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof |
US8641418B2 (en) | 2010-03-29 | 2014-02-04 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
US20120136416A1 (en) * | 2010-11-19 | 2012-05-31 | President And Fellows Of Harvard College | Caged Neuropeptides: modulation and measurement of synapse and signaling activity; and methods for drug evaluation, pharmaceuticals preparation and treatment |
ES2580207T3 (en) * | 2010-12-17 | 2016-08-22 | Eyesense Ag | High sensitivity competitive biosensor |
WO2012116013A2 (en) * | 2011-02-22 | 2012-08-30 | Wackett Lawrence P | Silica encapsulated biomaterials |
WO2013070778A1 (en) | 2011-11-07 | 2013-05-16 | Regents Of The University Of Minnesota | Silica-matrix forming compositions, materials formed therefrom, and methods of using the same |
US9131995B2 (en) | 2012-03-20 | 2015-09-15 | Biomet 3I, Llc | Surface treatment for an implant surface |
IN2014DN09299A (en) * | 2012-04-06 | 2015-07-10 | Akermin Inc | |
EA201590165A1 (en) | 2012-07-06 | 2015-08-31 | Эгалет Лтд. | CONTAINING ABUSE OF PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED LIBERATION |
US9687465B2 (en) | 2012-11-27 | 2017-06-27 | Sol-Gel Technologies Ltd. | Compositions for the treatment of rosacea |
US9534236B2 (en) | 2013-03-08 | 2017-01-03 | Regents Of The University Of Minnesota | Membranes for wastewater-generated energy and gas |
EP2995684B1 (en) | 2013-05-07 | 2019-07-03 | Korea University Research and Business Foundation | Recombinant microorganism metabolizing 3,6-anhydride-l-galactose and a use thereof |
US10125105B2 (en) | 2014-06-11 | 2018-11-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Triazabutadienes as cleavable cross-linkers |
US9593080B1 (en) | 2014-06-11 | 2017-03-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Triazabutadienes as cleavable cross-linkers |
WO2015191735A1 (en) | 2014-06-11 | 2015-12-17 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Water-soluble triazabutadienes |
US10035719B2 (en) | 2014-10-15 | 2018-07-31 | Regents Of The University Of Minnesota | System and membrane for wastewater-generated energy and gas |
US10954195B2 (en) | 2015-08-11 | 2021-03-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted triazenes protected from degradation by carboxylation of N1 |
EP3452023A1 (en) | 2016-05-05 | 2019-03-13 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
US11339129B2 (en) | 2016-07-29 | 2022-05-24 | Arizona Board of Regents on behalf of the University of Arizon | Triazabutadienes as cleavable cross-linkers |
GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
US10933061B2 (en) | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
CN110343690B (en) * | 2018-04-05 | 2021-12-07 | 宁波酶赛生物工程有限公司 | Decarboxylase polypeptide and application thereof in preparation of tyramine and dopamine |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
CN109022413A (en) * | 2018-08-10 | 2018-12-18 | 暨南大学 | A kind of monoamine oxidase A microreactor and its preparation method and application |
JP2023538859A (en) * | 2020-08-31 | 2023-09-12 | パーデュー、ファーマ、リミテッド、パートナーシップ | Compositions and methods for levodopa delivery |
CN112716895A (en) * | 2020-12-18 | 2021-04-30 | 济南大学 | Andrographolide drug-loaded micelle of Pluronic F127 modified based on phenylbutyric acid and preparation method thereof |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54143588A (en) * | 1978-04-25 | 1979-11-08 | Unitika Ltd | Preparation of sterilized, immobilized enzyme |
JPS60120987A (en) * | 1983-12-05 | 1985-06-28 | Kikkoman Corp | Production of immobilized microbial cell or enzyme |
US5189064A (en) | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
US5510254A (en) * | 1986-04-18 | 1996-04-23 | Advanced Tissue Sciences, Inc. | Three dimensional cell and tissue culture system |
IL84110A (en) | 1986-10-14 | 1992-11-15 | Lilly Co Eli | Process for transforming a human insulin precursor to a human insulin |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5786216A (en) | 1987-11-17 | 1998-07-28 | Cytotherapeutics, Inc. | Inner-supported, biocompatible cell capsules |
US5773286A (en) | 1987-11-17 | 1998-06-30 | Cytotherapeutics, Inc. | Inner supported biocompatible cell capsules |
JP2688596B2 (en) * | 1988-08-05 | 1997-12-10 | 株式会社ワイエムシィ | Enzyme-immobilized column packing material |
US5665589A (en) | 1988-12-14 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Human liver epithelial cell lines |
US5770416A (en) | 1989-05-26 | 1998-06-23 | Upfront Chromatography A/S | Permeable hollow particles having an outer shell of mechanically rigid porous material |
IL93134A (en) | 1990-01-23 | 1997-11-20 | Yissum Res Dev Co | Doped sol-gel glasses for obtaining chemical interactions |
US5371018A (en) | 1990-01-23 | 1994-12-06 | Yissum, Research Development Company Of The Hebrew University Of Jerusalem | Qualitative and quantitative processes for reactive chemicals in liquids using doped sol-gel glasses |
US5308495A (en) | 1990-01-23 | 1994-05-03 | Yissum, Research Development Company Of The Hebrew University Of Jerusalem | Chromatography processes using doped sol gel glasses as chromatographic media |
DK165090D0 (en) * | 1990-07-09 | 1990-07-09 | Kem En Tec As | CONLOMERATED PARTICLES |
US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
US5204369A (en) | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
US5378232A (en) | 1991-08-28 | 1995-01-03 | Orion Therapeutic Systems, Inc. | Injection/activation apparatus |
JPH0587811A (en) * | 1991-09-30 | 1993-04-06 | Konica Corp | Manufacture of carrier for fixing |
ES2149768T3 (en) * | 1992-03-25 | 2000-11-16 | Immunogen Inc | CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065. |
GB9314960D0 (en) | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
JPH06126134A (en) * | 1992-10-13 | 1994-05-10 | Osaka Gas Co Ltd | Method for purification of nitrogen oxide in exhaust gas |
US5693513A (en) * | 1995-01-10 | 1997-12-02 | Pope; Edward J. A. | Encapsulation of living tissue cells in an organosilicon |
CA2169292C (en) | 1993-08-12 | 2010-11-23 | E. Edward Baetge | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
EP0647450A1 (en) * | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
DE4342770A1 (en) | 1993-12-15 | 1995-07-06 | Boehringer Mannheim Gmbh | Carrier-fixed enzymes |
US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
US5817327A (en) | 1994-07-27 | 1998-10-06 | The Trustees Of The University Of Pennsylvania | Incorporation of biologically active molecules into bioactive glasses |
JPH08131190A (en) * | 1994-11-10 | 1996-05-28 | New Japan Radio Co Ltd | Biosensor |
US5840307A (en) | 1995-03-31 | 1998-11-24 | Immulogic Pharmacuetical Corp. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation |
US5759539A (en) | 1995-06-06 | 1998-06-02 | Georgia Research Foundation, Inc. | Method for rapid enzymatic alcohol removal |
SI0795334T1 (en) * | 1996-03-12 | 2006-06-30 | Sanofi Aventis Deutschland | Prodrugs for the treatment tumors and inflammatory diseases |
JP2862509B2 (en) * | 1996-05-28 | 1999-03-03 | 東洋電化工業株式会社 | Carrier for lipase immobilization and immobilized lipase |
HU227939B1 (en) | 1996-05-29 | 2012-06-28 | Delsitech Oy | Dissolvable oxides for biological applications |
US5849371A (en) * | 1996-07-22 | 1998-12-15 | Beesley; Dwayne | Laser and laser-assisted free electron beam deposition apparatus and method |
JP4061415B2 (en) * | 1998-09-10 | 2008-03-19 | 東洋紡績株式会社 | Immobilization carrier, immobilized enzyme preparation and production method thereof |
-
2000
- 2000-02-14 JP JP2000598187A patent/JP4812167B2/en not_active Expired - Fee Related
- 2000-02-14 CA CA2328614A patent/CA2328614C/en not_active Expired - Fee Related
- 2000-02-14 AU AU27599/00A patent/AU772153B2/en not_active Ceased
- 2000-02-14 WO PCT/US2000/003754 patent/WO2000047236A1/en active IP Right Grant
- 2000-02-14 US US09/503,438 patent/US6395299B1/en not_active Expired - Fee Related
- 2000-02-14 IL IL13899000A patent/IL138990A0/en not_active IP Right Cessation
-
2002
- 2002-02-15 US US10/077,475 patent/US20030082238A1/en not_active Abandoned
-
2004
- 2004-05-04 US US10/838,423 patent/US7052913B2/en not_active Expired - Fee Related
-
2006
- 2006-05-15 US US11/434,488 patent/US20070098807A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6395299B1 (en) | 2002-05-28 |
AU2759900A (en) | 2000-08-29 |
CA2328614A1 (en) | 2000-08-17 |
IL138990A0 (en) | 2001-11-25 |
AU772153B2 (en) | 2004-04-08 |
US7052913B2 (en) | 2006-05-30 |
US20030082238A1 (en) | 2003-05-01 |
JP2002536422A (en) | 2002-10-29 |
WO2000047236A1 (en) | 2000-08-17 |
CA2328614C (en) | 2012-06-26 |
US20070098807A1 (en) | 2007-05-03 |
US20040241205A1 (en) | 2004-12-02 |
JP4812167B2 (en) | 2011-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000047236A8 (en) | Matrices for drug delivery and methods for making and using the same | |
Obeso et al. | The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease | |
UA29563C2 (en) | Microcapsule for prolonged release of physiologically active peptide | |
AU1369297A (en) | Medical implant | |
EA200300046A1 (en) | QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION | |
WO2002004001A3 (en) | A composition for the delivery of live cells and methods of use | |
WO2005000266A3 (en) | Liposomal formulations comprising a combination of two or more active agents | |
DE69529054D1 (en) | TARGETED ACTIVE SUBSTANCE SYSTEM, METHOD FOR THE PRODUCTION AND USE THEREOF | |
NZ272610A (en) | The manufacture of dispersible tablets containing fluoxetine by direct compression | |
CA2444561A1 (en) | Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation | |
ZA200209980B (en) | Improved transdermal-treatment of parkinson's disease. | |
CA2319946A1 (en) | Implant-supported dental prosthesis and a process for its production | |
EP1143950A3 (en) | Topical application products | |
PT1317419E (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
IT1307829B1 (en) | DENTAL PROSTHESIS WITH MEANS FOR THE RELEASE OF DRUGS OR SPECIFIC FACTORS TO PREVENT THE ONset OF INFECTIONS AND / OR PROMOTE | |
WO2005068498A3 (en) | Human therapeutic cells secreting nerve growth factor | |
NZ514129A (en) | Tolperison-containing, pharmaceutical preparation for oral administration | |
WO1999015643A3 (en) | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | |
IL150818A0 (en) | Composition for intestinal delivery | |
YU68702A (en) | Novel lhrh-antagonists, production and use thereof as medicament | |
MXPA04003506A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease. | |
BR0008739A (en) | Controlled-release compositions of beta-histine | |
MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
EP1108429A3 (en) | An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases | |
CN2933334Y (en) | Artificial planting denture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 27599/00 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2328614 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 138990 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 33/2000 UNDER (81) ADD "US" |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
WWG | Wipo information: grant in national office |
Ref document number: 27599/00 Country of ref document: AU |